News Merck buys Silence and its siRNA pipeline for $1.3bn Merck KGaA is slated to acquire UK-based Silence Therapeutics in a $1.3bn deal that would give it a late-stage drug for polycythemia vera.
News FDA clears Takeda, Protagonist's first-in-class PV drug Takeda and Protagonist's hepcidin mimetic rusfertide is the first hepcidin mimetic to be approved by the FDA for blood cancer polycythaemia vera.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.